Sunday, June 25, 2017 6:59:10 PM
I think it will be a combination of encoded IL-12, an adjuvant with tumor-specific antigen, an expression promotor, and a co-stimulatory molecule.
Based on existing data, the P2A link leads to statistically significant changes in protein expressions. This is quite a big deal if you're trying to elevate Interleukin 12 expression and resulting interferon gamma and PDL1 levels. Nonresponders consistently show low levels of both.
Low voltage leads to vast improvements in transfection rates.
I am basing all of this on presentations and patents filings.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM